Literature DB >> 11901189

Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF.

Vassiliki Poulaki1, Wenying Qin, Antonia M Joussen, Peter Hurlbut, Stanley J Wiegand, John Rudge, George D Yancopoulos, Anthony P Adamis.   

Abstract

Acute intensive insulin therapy is an independent risk factor for diabetic retinopathy. Here we demonstrate that acute intensive insulin therapy markedly increases VEGF mRNA and protein levels in the retinae of diabetic rats. Retinal nuclear extracts from insulin-treated rats contain higher hypoxia-inducible factor-1alpha (HIF-1alpha) levels and demonstrate increased HIF-1alpha-dependent binding to hypoxia-responsive elements in the VEGF promoter. Blood-retinal barrier breakdown is markedly increased with acute intensive insulin therapy but can be reversed by treating animals with a fusion protein containing a soluble form of the VEGF receptor Flt; a control fusion protein has no such protective effect. The insulin-induced retinal HIF-1alpha and VEGF increases and the related blood-retinal barrier breakdown are suppressed by inhibitors of p38 mitogen-activated protein kinase (MAPK) and phosphatidylinositol (PI) 3-kinase, but not inhibitors of p42/p44 MAPK or protein kinase C. Taken together, these findings indicate that acute intensive insulin therapy produces a transient worsening of diabetic blood-retinal barrier breakdown via an HIF-1alpha-mediated increase in retinal VEGF expression. Insulin-induced VEGF expression requires p38 MAPK and PI 3-kinase, whereas hyperglycemia-induced VEGF expression is HIF-1alpha-independent and requires PKC and p42/p44 MAPK. To our knowledge, these data are the first to identify a specific mechanism for the transient worsening of diabetic retinopathy, specifically blood-retinal barrier breakdown, that follows the institution of intensive insulin therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11901189      PMCID: PMC150907          DOI: 10.1172/JCI13776

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus.

Authors:  M Henricsson; A Nilsson; L Janzon; L Groop
Journal:  Diabet Med       Date:  1997-02       Impact factor: 4.359

2.  Independent regulation of JNK/p38 mitogen-activated protein kinases by metabolic oxidative stress in the liver.

Authors:  K G Mendelson; L R Contois; S G Tevosian; R J Davis; K E Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

3.  Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization.

Authors:  M Grant; B Russell; C Fitzgerald; T J Merimee
Journal:  Diabetes       Date:  1986-04       Impact factor: 9.461

4.  Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension.

Authors:  B H Jiang; G L Semenza; C Bauer; H H Marti
Journal:  Am J Physiol       Date:  1996-10

5.  Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.

Authors:  G J Brunn; J Williams; C Sabers; G Wiederrecht; J C Lawrence; R T Abraham
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

6.  Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.

Authors:  S Savage; R O Estacio; B Jeffers; R W Schrier
Journal:  Proc Assoc Am Physicians       Date:  1997-03

7.  Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate.

Authors:  M J Tolentino; J W Miller; E S Gragoudas; F A Jakobiec; E Flynn; K Chatzistefanou; N Ferrara; A P Adamis
Journal:  Ophthalmology       Date:  1996-11       Impact factor: 12.079

8.  Isolation and expression of cDNAs from rainbow trout (Oncorhynchus mykiss) that encode two novel basic helix-loop-Helix/PER-ARNT-SIM (bHLH/PAS) proteins with distinct functions in the presence of the aryl hydrocarbon receptor. Evidence for alternative mRNA splicing and dominant negative activity in the bHLH/PAS family.

Authors:  R S Pollenz; H R Sullivan; J Holmes; B Necela; R E Peterson
Journal:  J Biol Chem       Date:  1996-11-29       Impact factor: 5.157

9.  Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit.

Authors:  L E Huang; Z Arany; D M Livingston; H F Bunn
Journal:  J Biol Chem       Date:  1996-12-13       Impact factor: 5.157

10.  Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo.

Authors:  M Kuroki; E E Voest; S Amano; L V Beerepoot; S Takashima; M Tolentino; R Y Kim; R M Rohan; K A Colby; K T Yeo; A P Adamis
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

View more
  78 in total

1.  Different effects of low- and high-dose insulin on ROS production and VEGF expression in bovine retinal microvascular endothelial cells in the presence of high glucose.

Authors:  Haixiang Wu; Chunhui Jiang; Dekang Gan; Yujie Liao; Hui Ren; Zhongcui Sun; Meng Zhang; Gezhi Xu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-15       Impact factor: 3.117

2.  Hypoxia inducible factor-1 mediates effects of insulin on pancreatic cancer cells and disturbs host energy homeostasis.

Authors:  Feng Wang; Shu Shun Li; Ralf Segersvärd; Lisa Strömmer; Karl-Gösta Sundqvist; Jan Holgersson; Johan Permert
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 3.  Hypoxic preconditioning protects against ischemic brain injury.

Authors:  Frank R Sharp; Ruiqiong Ran; Aigang Lu; Yang Tang; Kenneth I Strauss; Todd Glass; Tim Ardizzone; Myriam Bernaudin
Journal:  NeuroRx       Date:  2004-01

Review 4.  Vascular dysfunction in the diabetic placenta: causes and consequences.

Authors:  Lopa Leach; Alice Taylor; Flavia Sciota
Journal:  J Anat       Date:  2009-07       Impact factor: 2.610

5.  Extract of Litsea japonica ameliorates blood-retinal barrier breakdown in db/db mice.

Authors:  Junghyun Kim; Chan-Sik Kim; Ik Soo Lee; Yun Mi Lee; Eunjin Sohn; Kyuhyung Jo; Joo Hwan Kim; Jin Sook Kim
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

6.  Hypoxia and the expression of HIF-1alpha and HIF-2alpha in the retina of streptozotocin-injected mice and rats.

Authors:  William S Wright; Robert M McElhatten; Jodine E Messina; Norman R Harris
Journal:  Exp Eye Res       Date:  2009-12-11       Impact factor: 3.467

7.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

8.  Active HIF-1 in the normal human retina.

Authors:  John M Hughes; Arjan J Groot; Petra van der Groep; René Sersansie; Marc Vooijs; Paul J van Diest; Cornelis J F Van Noorden; Reinier O Schlingemann; Ingeborg Klaassen
Journal:  J Histochem Cytochem       Date:  2009-11-09       Impact factor: 2.479

9.  Antipermeability function of PEDF involves blockade of the MAP kinase/GSK/beta-catenin signaling pathway and uPAR expression.

Authors:  Jinling Yang; Elia J Duh; Ruth B Caldwell; M Ali Behzadian
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

10.  Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases.

Authors:  Alexa Klettner; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-15       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.